Twist Bioscience Co. (NASDAQ:TWST) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Twist Bioscience Co. (NASDAQ:TWST) has been assigned a consensus recommendation of “Moderate Buy” from the nine brokerages that are covering the firm, Marketbeat reports. One analyst has rated the stock with a sell recommendation and eight have issued a buy recommendation on the company. The average 1 year price target among brokerages that have covered the stock in the last year is $48.22.

Several brokerages have recently weighed in on TWST. Barclays dropped their price objective on shares of Twist Bioscience from $60.00 to $55.00 and set an “overweight” rating on the stock in a research report on Monday, August 5th. JPMorgan Chase & Co. increased their price objective on shares of Twist Bioscience from $28.00 to $35.00 and gave the company an “underweight” rating in a research report on Monday, August 5th. TD Cowen increased their price objective on shares of Twist Bioscience from $55.00 to $65.00 and gave the company a “buy” rating in a research report on Thursday, June 13th. Robert W. Baird increased their price objective on shares of Twist Bioscience from $40.00 to $46.00 and gave the company an “outperform” rating in a research report on Monday, August 5th. Finally, Guggenheim assumed coverage on shares of Twist Bioscience in a research report on Tuesday, June 4th. They issued a “buy” rating and a $53.00 price objective on the stock.

Insider Buying and Selling at Twist Bioscience

In other Twist Bioscience news, COO Patrick John Finn sold 2,207 shares of the firm’s stock in a transaction dated Tuesday, July 23rd. The shares were sold at an average price of $56.62, for a total value of $124,960.34. Following the transaction, the chief operating officer now directly owns 171,212 shares of the company’s stock, valued at approximately $9,694,023.44. The transaction was disclosed in a legal filing with the SEC, which is available through this link. In other Twist Bioscience news, COO Patrick John Finn sold 2,207 shares of the firm’s stock in a transaction dated Tuesday, July 23rd. The shares were sold at an average price of $56.62, for a total value of $124,960.34. Following the transaction, the chief operating officer now directly owns 171,212 shares of the company’s stock, valued at approximately $9,694,023.44. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Dennis Cho sold 709 shares of the firm’s stock in a transaction that occurred on Monday, August 5th. The shares were sold at an average price of $39.93, for a total transaction of $28,310.37. Following the completion of the sale, the insider now owns 78,996 shares in the company, valued at $3,154,310.28. The disclosure for this sale can be found here. Insiders have sold a total of 17,483 shares of company stock valued at $781,448 in the last ninety days. 3.92% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Twist Bioscience

A number of hedge funds have recently made changes to their positions in the stock. American International Group Inc. boosted its stake in shares of Twist Bioscience by 0.8% in the 1st quarter. American International Group Inc. now owns 28,506 shares of the company’s stock valued at $978,000 after purchasing an additional 213 shares in the last quarter. Caprock Group LLC boosted its stake in shares of Twist Bioscience by 2.9% in the 2nd quarter. Caprock Group LLC now owns 7,851 shares of the company’s stock valued at $387,000 after purchasing an additional 220 shares in the last quarter. Arizona State Retirement System boosted its stake in shares of Twist Bioscience by 1.9% in the 2nd quarter. Arizona State Retirement System now owns 16,187 shares of the company’s stock valued at $798,000 after purchasing an additional 308 shares in the last quarter. Massachusetts Financial Services Co. MA boosted its position in Twist Bioscience by 3.5% during the 2nd quarter. Massachusetts Financial Services Co. MA now owns 9,279 shares of the company’s stock worth $457,000 after buying an additional 312 shares during the period. Finally, CWM LLC boosted its position in Twist Bioscience by 27.4% during the 2nd quarter. CWM LLC now owns 2,437 shares of the company’s stock worth $120,000 after buying an additional 524 shares during the period.

Twist Bioscience Price Performance

Shares of TWST stock opened at $37.26 on Thursday. The stock has a market cap of $2.18 billion, a P/E ratio of -11.09 and a beta of 1.76. The company has a fifty day moving average price of $47.98 and a two-hundred day moving average price of $42.65. Twist Bioscience has a one year low of $14.42 and a one year high of $60.90.

Twist Bioscience (NASDAQ:TWST) last announced its quarterly earnings results on Friday, August 2nd. The company reported ($1.47) EPS for the quarter, missing analysts’ consensus estimates of ($0.76) by ($0.71). The firm had revenue of $81.50 million during the quarter, compared to analyst estimates of $77.40 million. Twist Bioscience had a negative net margin of 74.63% and a negative return on equity of 32.17%. The business’s revenue was up 27.7% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($1.01) EPS. As a group, equities research analysts anticipate that Twist Bioscience will post -3.13 EPS for the current fiscal year.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.